Cytely AB raises capital to accelerate discoveries that can cure diseases

LUND, SWEDEN – Cytely has raised €3 million in a funding round led by Danish Ugly Duckling Ventures. The new capital will be used to support international expansion of the company’s AI-driven microscopy platform, which automates cell analysis and accelerates biomedical research.

 

Cytely’s smart microscopy platform is hardware-agnostic, transforming microscopes into real-time data engines. The platform eliminates manual bottlenecks and provides laboratories with statistically robust results in minutes instead of months.

 

The system is already being used by leading research institutions in Lund, Copenhagen, Amsterdam, Singapore, and San Diego, helping scientists achieve more progress in one month than in the previous five years.

 

“Cytely’s software is a democratizing force in science. It decouples world‑class discovery from world‑class funding, empowering any researcher with a microscope to tackle the biggest challenges in human health,” says Dr. Vinay Swaminathan, Head of the Laboratory of Cell & Molecular Mechanobiology at Lund University.

 

Traditional microscopy has long been based on images, making analysis slow and data limited. Cytely addresses today’s bottlenecks by making data the primary product—standardized, quantitative, and reproducible—allowing researchers to make faster and more reliable decisions.

 

"Scientists have been constrained by workflows built for images, not data. Cytely transforms any microscope into a real-time measurement instrument, closing the loop from acquisition to decision on an experiment-day timescale rather than a grant cycle,” says Philip Nordenfelt, Cytely co-founder & CEO.

 

With the new funding, Cytely will further develop its AI platform to make it even more intuitive, enable collaboration between researchers, and expand operations in the U.S. and Asia. The long-term goal is to build a global discovery system that helps scientists make breakthroughs faster and eventually predict outcomes and autonomously drive parts of the research process.

 

Cytely is one of SmiLe Venture Hub’s portfolio companies.

 

 

Read a more detailed pressrelease here.

 

For more information, please contact

Philip Nordenfelt, CEO, Cytely

philip@cytely.io

About Cytely
Cytely is a deeptech startup focused on accelerating discovery to unlock human biology and cure all preventable disease. The company's smart-microscopy platform turns images into data, quantifying thousands of cells per run, automating acquisition, and standardizing analysis so researchers can discover and iterate faster. Built with transparent methods and a modern web interface, Cytely powers the shift to data-centric workflows and works with any modern microscope. The team is globally distributed with founders located across the globe, specifically Lund, San Diego and Singapore.
https://www.cytely.io/

---

---